MCID: LNG020
MIFTS: 53

Lung Oat Cell Carcinoma

Categories: Cancer diseases, Respiratory diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Lung Oat Cell Carcinoma

MalaCards integrated aliases for Lung Oat Cell Carcinoma:

Name: Lung Oat Cell Carcinoma 11 5 14
Carcinoma, Small Cell 43
Oat Cell Carcinoma 11
Carcinoma Oat Cell 53

Classifications:



External Ids:

Disease Ontology 11 DOID:5411
MeSH 43 D018288
NCIt 49 C3915
SNOMED-CT 68 11010461000119101
UMLS 71 C0262584

Summaries for Lung Oat Cell Carcinoma

MalaCards based summary: Lung Oat Cell Carcinoma, also known as carcinoma, small cell, is related to esophagus small cell carcinoma and prostate small cell carcinoma. An important gene associated with Lung Oat Cell Carcinoma is RB1 (RB Transcriptional Corepressor 1), and among its related pathways/superpathways are Disease and Cytokine Signaling in Immune system. The drugs BCG vaccine and Atezolizumab have been mentioned in the context of this disorder. Affiliated tissues include lung, cervix and prostate, and related phenotypes are nervous system and neoplasm

Related Diseases for Lung Oat Cell Carcinoma

Diseases related to Lung Oat Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 521)
# Related Disease Score Top Affiliating Genes
1 esophagus small cell carcinoma 32.4 PIK3CA ENO2
2 prostate small cell carcinoma 31.8 SYP ENO2
3 gallbladder small cell carcinoma 31.4 SYP ENO2 CHGA
4 carcinoid tumors, intestinal 30.4 SYP ENO2 CHGA
5 squamous cell carcinoma 30.4 TP53 RB1 PTEN PIK3CA AKT1
6 inappropriate adh syndrome 30.3 POMC ENO2 AVP
7 carcinoid syndrome 30.2 SYP ENO2 CHGA
8 small cell carcinoma 30.0 TP53 SYP PTEN ENO2 CHGA
9 sarcoma 30.0 TP53 RB1 PIK3CA ENO2
10 gallbladder adenocarcinoma 30.0 TP53 SYP CHGA
11 papilloma 29.9 TP53 RB1 PTEN AKT1
12 bladder small cell carcinoma 29.8 SYP ENO2
13 esophageal cancer 29.8 TP53 RB1 PTEN PIK3CA AKT1
14 acquired immunodeficiency syndrome 29.8 TP53 POMC B2M
15 myeloma, multiple 29.8 TP53 RB1 PIK3CA B2M AKT1
16 mismatch repair cancer syndrome 29.8 TP53 PTEN PIK3CA
17 diffuse gastric cancer 29.8 TP53 PTEN PIK3CA
18 ductal carcinoma in situ 29.8 TP53 PTEN PIK3CA AKT1
19 cholangiocarcinoma 29.8 TP53 PTEN PIK3CA AKT1
20 transitional cell carcinoma 29.7 TP53 PTEN ENO2
21 large cell carcinoma 29.7 TP53 SYP ENO2 CHGA
22 adenocarcinoma 29.6 TP53 RB1 PTEN PIK3CA CHGA AKT1
23 gallbladder cancer 29.6 TP53 RB1 PTEN PIK3CA AKT1
24 conn's syndrome 29.5 TP53 SYP POMC CHGA AVP
25 head and neck cancer 29.5 TP53 PTEN PIK3CA AKT1
26 merkel cell carcinoma 29.4 SYP ENO2 CHGA
27 lung cancer susceptibility 3 29.4 TP53 RB1 PIK3CA B2M AKT1
28 neuroendocrine carcinoma 29.4 SYP PTEN ENO2 CHGA
29 bladder urothelial carcinoma 29.4 TP53 RB1 PTEN PIK3CA AKT1
30 squamous cell carcinoma, head and neck 29.3 TP53 RB1 PTEN PIK3CA B2M AKT1
31 multiple endocrine neoplasia 29.3 SYP POMC CHGA
32 tubular adenocarcinoma 29.2 SYP ENO2 CHGA
33 thyroid gland medullary carcinoma 29.1 SYP POMC CHGA
34 wilms tumor 1 29.0 TP53 SYP PTEN ENO2 AKT1
35 lung benign neoplasm 29.0 TP53 SYP RB1 ENO2 CHGA
36 large cell neuroendocrine carcinoma 29.0 TP53 SYP ENO2 CHGA
37 lung large cell carcinoma 29.0 TP53 SYP ENO2 CHGA
38 mixed cell type cancer 29.0 TP53 SYP PTEN PIK3CA ENO2 CHGA
39 islet cell tumor 29.0 SYP POMC ENO2 CHGA
40 pheochromocytoma 29.0 SYP POMC ENO2 CHGA
41 melanoma 28.9 TP53 RB1 PTEN POMC PIK3CA ENO2
42 adenoma 28.6 TP53 SYP POMC PIK3CA CHGA AKT1
43 medulloblastoma 28.5 TP53 SYP RB1 PTEN PIK3CA ENO2
44 pancreatic cancer 28.5 TP53 SYP RB1 PTEN PIK3CA CHGA
45 lung cancer 28.4 TP53 SYP RB1 PTEN PIK3CA ENO2
46 suppression of tumorigenicity 12 28.4 TP53 SYP PTEN PIK3CA ENO2 CHGA
47 neuroblastoma 28.4 TP53 SYP PTEN PIK3CA ENO2 CHGA
48 small cell cancer of the lung 27.5 TP53 SYP RB1 PTEN POMC PIK3CA
49 nervous system disease 27.5 TP53 SYP RB1 PTEN POMC PIK3CA
50 trachea carcinoma 10.4

Graphical network of the top 20 diseases related to Lung Oat Cell Carcinoma:



Diseases related to Lung Oat Cell Carcinoma

Symptoms & Phenotypes for Lung Oat Cell Carcinoma

MGI Mouse Phenotypes related to Lung Oat Cell Carcinoma:

45 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 10.22 AKT1 AVP B2M CHGA ENO2 PIK3CA
2 neoplasm MP:0002006 10.05 AKT1 B2M PIK3CA POMC PTEN RB1
3 no phenotypic analysis MP:0003012 9.97 AVP CHGA PIK3CA POMC RB1 TP53
4 growth/size/body region MP:0005378 9.97 AKT1 B2M CHGA ENO2 PIK3CA POMC
5 renal/urinary system MP:0005367 9.93 AVP CHGA POMC PTEN RB1 TP53
6 muscle MP:0005369 9.91 AKT1 CHGA PIK3CA PTEN RB1 TP53
7 liver/biliary system MP:0005370 9.88 AKT1 B2M POMC PTEN RB1 TP53
8 endocrine/exocrine gland MP:0005379 9.86 AKT1 B2M CHGA PIK3CA POMC PTEN
9 adipose tissue MP:0005375 9.85 AKT1 PIK3CA POMC PTEN RB1 TP53
10 cardiovascular system MP:0005385 9.76 AKT1 B2M CHGA PIK3CA POMC PTEN
11 behavior/neurological MP:0005386 9.61 AKT1 AVP ENO2 PIK3CA POMC PTEN
12 integument MP:0010771 9.17 AKT1 B2M PIK3CA POMC PTEN RB1

Drugs & Therapeutics for Lung Oat Cell Carcinoma

Drugs for Lung Oat Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 149)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
BCG vaccine Approved, Investigational Phase 3
2
Atezolizumab Approved, Investigational Phase 2, Phase 3 1380723-44-3
3
Memantine Approved, Investigational Phase 3 41100-52-1, 19982-08-2 4054
4
Dopamine Approved Phase 3 62-31-7, 51-61-6 681
5
Cisplatin Approved Phase 3 15663-27-1 2767 5702198 441203
6
Carboplatin Approved Phase 3 41575-94-4 10339178 38904
7
Etoposide Approved Phase 3 33419-42-0 36462
8
Belotecan Investigational Phase 3 256411-32-2 9824190
9 Vaccines Phase 3
10
Epoetin Alfa Phase 3
11 Hematinics Phase 3
12 Immunologic Factors Phase 2, Phase 3
13 Neurotransmitter Agents Phase 3
14 Dopamine Agents Phase 3
15 Antiparkinson Agents Phase 3
16 Excitatory Amino Acid Antagonists Phase 3
17
Etoposide phosphate Phase 3 16760419
18
Bevacizumab Approved, Investigational Phase 2 216974-75-3 135329020
19
Somatostatin Approved, Investigational Phase 1, Phase 2 38916-34-6, 51110-01-1 53481605 16129706
20
Arsenic trioxide Approved, Investigational Phase 2 1327-53-3 518740
21
Vinorelbine Approved, Investigational Phase 2 71486-22-1 44424639 60780
22
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
23
Lenograstim Approved, Investigational Phase 2 135968-09-1
24
Temozolomide Approved, Investigational Phase 1, Phase 2 85622-93-1 5394
25
Irinotecan Approved, Investigational Phase 1, Phase 2 97682-44-5, 100286-90-6 60838
26
Lamivudine Approved, Investigational Phase 2 134678-17-4 60825
27
Rucaparib Approved, Investigational Phase 1, Phase 2 283173-50-2 9931954
28
Niraparib Approved, Investigational Phase 1, Phase 2 1038915-60-4 24958200
29
Erlotinib Approved, Investigational Phase 2 183319-69-9, 183321-74-6 176870
30
Lapatinib Approved, Investigational Phase 2 231277-92-2, 388082-78-8 208908
31
Sunitinib Approved, Investigational Phase 2 557795-19-4 5329102
32
Talazoparib Approved, Investigational Phase 2 1207456-01-6 135565082
33
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
34
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
35
Methyltestosterone Approved Phase 2 58-18-4 6010
36
Testosterone undecanoate Approved, Investigational Phase 2 5949-44-0 21873174 65157
37
Testosterone enanthate Approved Phase 2 315-37-7 9416
38
Testosterone Approved, Investigational Phase 2 58-22-0 5408 6013
39
Nivolumab Approved Phase 2 946414-94-4
40
Ipilimumab Approved Phase 2 477202-00-9
41
Durvalumab Approved, Investigational Phase 2 1428935-60-7
42
Topotecan Approved, Investigational Phase 2 123948-87-8, 119413-54-6 60699 60700
43
Pomalidomide Approved Phase 1, Phase 2 19171-19-8 134780
44
Levoleucovorin Approved, Experimental, Investigational Phase 1, Phase 2 68538-85-2, 58-05-9, 73951-54-9 149436 6006
45
Pemetrexed Approved, Investigational Phase 1, Phase 2 150399-23-8, 137281-23-3 60843 446556 135565230
46
Gemcitabine Approved Phase 2 95058-81-4, 122111-03-9 60750
47
Bemiparin Approved, Investigational Phase 2 91449-79-5
48
Zoledronic acid Approved Phase 2 118072-93-8 68740
49
Picropodophyllin Approved, Investigational Phase 2 518-28-5, 477-47-4 10607 72435
50
Olaparib Approved Phase 2 763113-22-0 23725625

Interventional clinical trials:

(show top 50) (show all 139)
# Name Status NCT ID Phase Drugs
1 Phase III Randomized Study of Hypofractionated vs Conventionally Fractionated Concurrent Chemo-radiotherapy for Limited Disease Small Cell Lung Cancer Unknown status NCT02688036 Phase 3
2 A Randomized Prospective Multicenter Trial of Belotecan/Cisplatin Versus Etoposide/Cisplatin in Patients With Previously Untreated, Extensive-stage Small-cell Lung Cancer Completed NCT00826644 Phase 3 Belotecan;Etoposide;Cisplatin
3 The SILVA Study: Survival in an International Phase III Prospective Randomized LD Small Cell Lung Cancer Vaccination Study With Adjuvant BEC2 and BCG Completed NCT00037713 Phase 3
4 A Placebo-Controlled Study on the Effect of Epoetin Alfa in Patients With Malignancy Receiving Chemotherapy Completed NCT00270166 Phase 3 epoetin alfa
5 Randomized Phase II/III Trial of First Line Platinum/Etoposide With or Without Atezolizumab (NSC#783608) in Patients With Poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC) Recruiting NCT05058651 Phase 2, Phase 3 Carboplatin;Cisplatin;Etoposide
6 Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab Recruiting NCT03811002 Phase 2, Phase 3 Atezolizumab;Carboplatin;Cisplatin;Etoposide
7 MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK) Recruiting NCT04155034 Phase 3
8 Randomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial Recruiting NCT04402788 Phase 2, Phase 3 Atezolizumab
9 Phase III Trial of Stereotactic Radiosurgery (SRS) Versus Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for 10 or Fewer Brain Metastases From Small Cell Lung Cancer Recruiting NCT04804644 Phase 3 Memantine Hydrochloride
10 REPLATINUM: A Phase 3, Controlled, Open-label, Global Randomized Study of RRx-001 Administered Sequentially With a Platinum Doublet or a Platinum Doublet in Third-Line or Beyond Small Cell Lung Cancer Active, not recruiting NCT05566041 Phase 3 RRx-001 + eLOOP Device;Cisplatin/carboplatin plus etoposide
11 A Phase 3, Controlled, Open-label, Randomized Study of RRx-001 Administered Sequentially With a Platinum Doublet or a Platinum Doublet in Third-Line or Beyond Small Cell Lung Cancer Terminated NCT03699956 Phase 3 Cisplatin/carboplatin plus etoposide
12 Phase 2 Study of Temozolomide as Maintenance Therapy After Initial Induction Chemotherapy in Small Cell Lung Cancer Unknown status NCT01900951 Phase 2 Temozolomide
13 Phase II Clinical Trial of Toripalimab (JS001), a Recombinant Humanized Anti-PD-1 Monoclonal PD1 Antibody, as Monotherapy for Patients With Small Cell Esophageal Carcinoma Who Failed Chemotherapy Unknown status NCT03811379 Phase 2 Toripalimab
14 Phase Ⅱ Study of Relationship Between UGT1A1 Gene Polymorphism and Toxicity and Efficacy of Irinotecan in Small Cell Lung Cancer Unknown status NCT01635400 Phase 2 Irinotecan
15 An Open-label Phase II Trial to Investigate the Efficacy, Safety, and Pharmacokinetics of a Single Dose of 200 mg i.v. BI 2536 Administered Every 21 Days in Patients With Sensitive Relapse Small Cell Lung Cancer Completed NCT00412880 Phase 2 BI 2536
16 A Phase I/II Study of Radiation Dose Intensity Concurrent With Chemotherapy For Limited Stage Small Cell Lung Cancer Completed NCT00126828 Phase 1, Phase 2
17 Phase II Trial of ALIMTA in Relapsed Small Cell Lung Cancer Completed NCT00191750 Phase 2 Pemetrexed
18 Phase I/II Study to Investigate the Safety, Tolerability, Efficacy and Pharmacokinetics of ZK 219477 in Combination With Cisplatin as First-line Therapy in Chemotherapy-naïve Patients With Extensive-disease (ED) Stage Small-cell Lung Cancer (SCLC) Completed NCT00359359 Phase 1, Phase 2 Sagopilone (BAY86-5302, ZK 219477);Cisplatin
19 Phase II Study of Irinotecan, Carboplatin, Bevacizumab, and Radiation Therapy in the Treatment of Patients With Limited Stage Small Cell Lung Cancer Completed NCT00308529 Phase 2 irinotecan;carboplatin;bevacizumab
20 A Phase II Trial of Topotecan and Carboplatin in the First-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer Completed NCT00305942 Phase 2 Topotecan;carboplatin
21 Phase 2 Open-Label, Multicenter Clinical Study of the Safety and Efficacy of Intravenous Administration of SNS-595 in Patients With Advanced Small Cell Lung Cancer (SCLC) Completed NCT00298896 Phase 2 SNS-595
22 A Phase II Trial of Irinotecan, Carboplatin, Bevacizumab in the Treatment of Patients With Extensive Stage Small Cell Lung Cancer Completed NCT00294931 Phase 2 irinotecan;carboplatin;bevacizumab
23 A Phase II Study Of Higher Dose Weekly Topotecan In The Treatment Of Patients With Extensive Stage Small-Cell Lung Cancer Completed NCT00294190 Phase 2 Topotecan
24 A Phase II Trial of VInflunine in the Treatment of Patients With Relapsed Extensive Small Cell Lung Cancer Completed NCT00284154 Phase 2 Vinflunine
25 Phase II Study to Determine the Efficacy of OSI-211 (Liposomal Lurtotecan) Given on Days 1, 2 & 3 Every 3 Weeks in Patients With Recurrent Small Cell Lung Cancer Completed NCT00046787 Phase 2 OSI-211 (Liposomal Lurtotecan)
26 A Phase 1/2a, Open-label Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of PEN-221 in Patients With Somatostatin Receptor 2 Expressing Advanced Cancers, Including Gastroenteropancreatic or Lung or Thymus or Other Neuroendocrine Tumors or Small Cell Lung Cancer or Large Cell Neuroendocrine Carcinoma of the Lung Completed NCT02936323 Phase 1, Phase 2 PEN-221
27 A Single Arm, Two-Stage Phase II Study of Arsenic Trioxide in Previously Treated Small Cell Lung Cancer Completed NCT01470248 Phase 2 Arsenic Trioxide
28 Combination Chemotherapy With or Without Maintenance Sunitinib Malate (NSC 736511) for Untreated Extensive Stage Small Cell Lung Cancer: A Phase IB/Randomized Phase II Study Completed NCT00453154 Phase 1, Phase 2 Carboplatin;Cisplatin;Etoposide;Sunitinib Malate
29 Utility of Preoperative FDG-PET/CT Scanning Prior to Primary Chemoradiation Therapy to Detect Retroperitoneal Lymph Node Metastasis in Patients With Locoregionally Advanced Carcinoma of the Cervix (IB2, IIA ≥ 4 CM, IIB-IVA) or Endometrium (Grade 3 Endometrioid Endometrial Carcinoma; Serous Papillary Carcinoma, Clear Cell Carcinoma, or Carcinosarcoma (Any Grade); and Grade 1 OR 2 Endometrioid Endometrial Carcinoma With Cervical Stromal Involvement Overt in Clinical Examination or Confirmed by Endocervical Curettage Completed NCT00416455 Phase 1, Phase 2 ferumoxtran-10
30 Phase I and Randomized Phase II Double Blind Clinical Trial of Cisplatin and Etoposide in Combination With Veliparib (ABT-888) or Placebo as Frontline Therapy for Extensive Stage Small Cell Lung Cancer Completed NCT01642251 Phase 1, Phase 2 Cisplatin;Etoposide;Veliparib;Placebo
31 Prospective Evaluation of Pelvic Exenteration in Patients With Recurrent Cervical Cancer Completed NCT00217633 Phase 2
32 A Phase II Evaluation of ABI-007 in the Treatment of Persistent or Recurrent Squamous or Nonsquamous Cell Carcinoma of the Cervix Completed NCT00309959 Phase 2 Paclitaxel Albumin-Stabilized Nanoparticle Formulation
33 A Clinical Trial of Increased Chest Radiotherapy Dose for Limited Stage Small Cell Lung Cancer Completed NCT00907569 Phase 2
34 A Phase II Study of RRx-001 in Platinum Refractory/Resistant Small Cell Carcinoma, EGFR TKI Resistant EGFR+ T790M Negative Non-Small Cell Lung Cancer, High Grade Neuroendocrine Tumors and Resistant/Refractory Ovarian Cancer Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT) Completed NCT02489903 Phase 2 RRx-001;Cisplatin;Etoposide;Carboplatin;Irinotecan;Vinorelbine;Doxil;Gemcitabine;Taxane;Paclitaxel;Nab-Paclitaxel;Pemetrexed
35 A Phase II Evaluation of ABT-888 (NCI Supplied Agent: ABT-888, NSC #737664), Topotecan (NSC # 609699) and Filgrastim or Pegfilgrastim in the Treatment of Persistent or Recurrent Squamous or Non-squamous Cell Carcinoma of the Cervix Completed NCT01266447 Phase 2 Topotecan Hydrochloride;Veliparib
36 PHASE 1-2 STUDY EVALUATING HIGH DOSE ADXS11-001 (1 x 10^10 CFU) TREATMENT IN WOMEN WITH HPV+ CARCINOMA OF THE CERVIX Completed NCT02164461 Phase 1, Phase 2
37 An Open Label Phase I/II Study of Cabazitaxel With or Without Carboplatin in Patients With Metastatic Castration-Resistant Prostate Cancer Completed NCT01505868 Phase 1, Phase 2 Cabazitaxel;Carboplatin
38 A Phase II Study of Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors Recruiting NCT03333616 Phase 2 Ipilimumab;Nivolumab
39 Safety Run-In and Phase II Trial of M7824 and Topotecan or Temozolomide in Relapsed Small Cell Cancers Recruiting NCT03554473 Phase 1, Phase 2 M7824;Topotecan;Temozolomide
40 Open Label Study of Single Dose Rhenium Re 188 P2045 in Patients With Lung Cancer Who Have Received or Refused to Receive Prior Chemotherapy Recruiting NCT00100256 Phase 1, Phase 2 Rhenium (Re 188 P2045, BAY86-5284)
41 A Phase II Trial of Lamivudine in Combination With Chemoimmunotherapy in Patients With Extensive Stage SCLC Recruiting NCT04696575 Phase 2 Carboplatin;Etoposide;Lamivudine
42 Phase II Clinical Trial of Durvalumab (MEDI4736) and Topotecan or Lurbinectedin in Patients With Relapsed Extensive Stage Small Cell Lung Cancer Previously Treated With Chemotherapy and Immunotherapy Recruiting NCT04607954 Phase 2 Lurbinectedin;Topotecan Hydrochloride
43 Phase II Study of AK104 (Cadonilimab) for Recurrent Small Cell Neuroendocrine Carcinomas of the Cervix Recruiting NCT05063916 Phase 2 AK104
44 Phase I/II Trial of PLX038 (PEGylated SN38) and Rucaparib in Solid Tumors and Small Cell Cancers Recruiting NCT04209595 Phase 1, Phase 2 PLX038;Rucaparib
45 A Study of Erdafitinib in Castration-Resistant Prostate Cancer Patients Evaluating Markers of Bone Remodeling and FGF Signaling in Plasma and Bone Marrow Recruiting NCT04754425 Phase 2 Erdafitinib
46 A Phase I/II Trial of PARP Inhibition, Radiation, and Immunotherapy in Patients With Extensive-Stage Small Cell Lung Cancer (ES-SCLC) - PRIO Trial Recruiting NCT04728230 Phase 1, Phase 2 Carboplatin;Etoposide;Olaparib
47 Phase 1b/2 Study of BXCL701, a Small Molecule Inhibitor of Dipeptidyl Peptidases, Administered in Combination With the Anti-Programmed Cell Death 1 Monoclonal Antibody Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype Recruiting NCT03910660 Phase 1, Phase 2 BXCL701 plus Pembrolizumab;BXCL701 monotherapy
48 A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC) Recruiting NCT03866382 Phase 2 Cabozantinib S-malate
49 An Open-Label Phase 1b Dose-Finding Trial Evaluating the Safety of Niraparib and Temozolomide and Atezolizumab in Participants With Advanced Solid Tumors and Expansion to a Phase 2 Trial Comparing the Effects of Niraparib and Temozolomide Plus Atezolizumab vs. Atezolizumab as Maintenance Therapy in Participants With Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line Chemotherapy (TRIO-US L-06) Recruiting NCT03830918 Phase 1, Phase 2 Niraparib;Temozolomide
50 Niraparib (PARP Inhibitor) Plus Dostarlimab (Anti-PD1) for Small Cell Lung Cancer (SCLC) and Other High-Grade Neuroendocrine Carcinomas (NEC) Recruiting NCT04701307 Phase 2 Niraparib

Search NIH Clinical Center for Lung Oat Cell Carcinoma

Cochrane evidence based reviews: carcinoma, small cell

Genetic Tests for Lung Oat Cell Carcinoma

Anatomical Context for Lung Oat Cell Carcinoma

Organs/tissues related to Lung Oat Cell Carcinoma:

MalaCards : Lung, Cervix, Prostate, Lymph Node, Thymus, Brain, Bone Marrow

Publications for Lung Oat Cell Carcinoma

Articles related to Lung Oat Cell Carcinoma:

(show top 50) (show all 754)
# Title Authors PMID Year
1
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. 5
26619011 2016
2
Prospective enterprise-level molecular genotyping of a cohort of cancer patients. 5
25157968 2014
3
Molecular profiling of small cell lung cancer in a Japanese cohort. 5
24657128 2014
4
Oncogenic point mutations in the human retinoblastoma gene: their application to genetic counseling. 5
2594029 1989
5
Neurophysins as markers of vasopressin and oxytocin release. A study in carcinoma of the lung. 53 62
1966564 1990
6
A Spoonful of Eponyms Helps the Pathology Go Down: Using Food Eponyms and Visual Mnemonics in Preclinical Pathology Education. 62
35154897 2022
7
Oat Cell Carcinoma Lung Presenting as Chest Wall Swelling. 62
34603878 2021
8
Managing Severe Dysgeusia and Dysosmia in Lung Cancer Patients: A Systematic Scoping Review. 62
34881185 2021
9
Calcitonin-Negative Neuroendocrine Carcinoma of the Thyroid Gland: Case Report and Literature Review. 62
33776692 2021
10
Nerve root metastasis of gastric adenocarcinoma: A case report and review of the literature. 62
31302320 2019
11
Oat-cell carcinoma of the tongue. 62
26956201 2016
12
Small cell carcinoma of the urinary bladder: changing trends in the current literature. 62
26889739 2016
13
The role of immunohistochemistry in the analysis of the spectrum of small round cell tumours at a tertiary care centre. 62
23998069 2013
14
Squamous cell carcinoma lung with progressive systemic sclerosis. 62
23781672 2012
15
Endoscopic ultrasound-guided biopsies for mediastinal lesions and lymph node diagnosis and staging. 62
22179163 2011
16
Neuroendocrine differentiation in prostate carcinoma: focusing on its pathophysiologic mechanisms and pathological features. 62
21232206 2010
17
Survival in a patient with severe paraneoplastic hyponatremia: a case report. 62
18928542 2008
18
Merkel cell carcinoma: treatment with bleomycin. 62
19061585 2008
19
[Small (oat)-cell carcinoma of the gastrointestinal tract]. 62
18341909 2008
20
Merkel cell carcinoma of the upper extremity: case report and an update. 62
18328106 2008
21
A note from history: the saga of carcinoid and oat-cell carcinoma. 62
18988939 2008
22
Cancer-associated retinopathy (CAR) with electronegative ERG: a case report. 62
17721792 2008
23
[Oat-cell carcinoma of the esophagus: presentation of two cases and literature review]. 62
17973588 2007
24
Isolated frontal disequilibrium as presenting form of anti-Hu paraneoplastic encephalomyelitis. 62
17266086 2007
25
F-18 FDG PET imaging of urinary bladder oat cell carcinoma with widespread osseous metastases. 62
16855436 2006
26
[Oat cell carcinoma of the common bile duct]. 62
16796953 2006
27
Oat cell carcinoma of the oesophagus--a case report and review of literature. 62
16498759 2005
28
[Diabetes insipidus in a patient with small-cell lung cancer: a paradox?]. 62
16392186 2005
29
[Neuroendocrine carcinomas of the cervix]. 62
15915327 2005
30
Extra-pulmonary oat cell carcinoma: report of two cases. 62
16022138 2005
31
(18)FDG PET in primary oat cell carcinoma of the esophagus. 62
15805695 2005
32
Primary oat cell carcinoma of the breast: imaging features. 62
15385324 2004
33
Small-cell carcinomas of the gastrointestinal tract: a review. 62
15226341 2004
34
Progressive encephalomyelitis with rigidity: a paraneoplastic presentation of oat cell carcinoma of the lung. Case report. 62
15273862 2004
35
[Paraneoplastic syndromes in ENT surgery]. 62
12682737 2003
36
Case report: esophageal collision tumor (oat cell carcinoma and adenocarcinoma) in Barrett's esophagus: immunohistochemical, electron microscopy and LOH analysis. 62
12507278 2003
37
Invasive papillary carcinomas of the extrahepatic bile ducts: a clinicopathologic and immunohistochemical study of 13 cases. 62
12481004 2002
38
Retinochoroidal mass: a presenting feature of metastatic oat cell carcinoma of lung. 62
12510727 2002
39
Synthesis, chemical, radiochemical and radiobiological evaluation of a new 99mTc-labelled bombesin-like peptide. 62
12136524 2002
40
Extrapulmonary oat-cell carcinoma presenting as a primary left ventricular tumor: a case report. 62
12011814 2002
41
[Oat cell carcinoma of the bladder]. 62
12090189 2002
42
[A case of central diabetes insipidus caused by metastatic small cell lung cancer]. 62
11974872 2002
43
Combined video-assisted mediastinoscopy and video-assisted thoracoscopy in the management of lung cancer. 62
11722067 2001
44
[Oat-cell carcinoma of the tongue: report of a case]. 62
11526653 2001
45
Paraneoplastic limbic encephalitis associated with bronchogenic carcinoma: a case report. 62
11447443 2001
46
Oat-cell carcinoma of the prostate. Diagnosis, prognosis and therapeutic implications. 62
11598447 2001
47
Metastases to the products of conception from a maternal bronchial carcinoma. A case report and review of literature. 62
11769401 2001
48
Lung cancer screening results in the National Cancer Institute New York study. 62
11147612 2000
49
Primary small cell (oat cell) carcinoma of the breast: report of a case and review of the literature. 62
11107070 2000
50
Bull's eye (target) inclusions in neoplastic cells in malignant serous effusions. A study of 289 cases. 62
10934946 2000

Variations for Lung Oat Cell Carcinoma

ClinVar genetic disease variations for Lung Oat Cell Carcinoma:

5 (show top 50) (show all 106)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 overlap with 54 genes t(2;2)(p23;p21)(hg19 chr2:g.42552694::ochr2:g.29446394) INVERS Pathogenic
487484 GRCh37: 2:29446394-42552694
GRCh38:
2 RB1 NM_000321.3(RB1):c.2242G>T (p.Glu748Ter) SNV Pathogenic
13078 rs121913297 GRCh37: 13:49039164-49039164
GRCh38: 13:48465028-48465028
3 RB1 NM_000321.3(RB1):c.1215+1G>A SNV Pathogenic
126832 rs587776783 GRCh37: 13:48947629-48947629
GRCh38: 13:48373493-48373493
4 RB1 NM_000321.3(RB1):c.1981C>T (p.Arg661Trp) SNV Pathogenic
13087 rs137853294 GRCh37: 13:49033844-49033844
GRCh38: 13:48459708-48459708
5 TP53 NM_000546.6(TP53):c.857A>G (p.Glu286Gly) SNV Likely Pathogenic
376590 rs1057519985 GRCh37: 17:7577081-7577081
GRCh38: 17:7673763-7673763
6 RB1 NM_000321.3(RB1):c.2117G>T (p.Cys706Phe) SNV Likely Pathogenic
376330 rs121913295 GRCh37: 13:49037877-49037877
GRCh38: 13:48463741-48463741
7 TP53 NM_000546.6(TP53):c.746G>T (p.Arg249Met) SNV Likely Pathogenic
376653 rs587782329 GRCh37: 17:7577535-7577535
GRCh38: 17:7674217-7674217
8 TP53 NM_000546.6(TP53):c.518T>G (p.Val173Gly) SNV Likely Pathogenic
376016 rs1057519747 GRCh37: 17:7578412-7578412
GRCh38: 17:7675094-7675094
9 TP53 NM_000546.6(TP53):c.821T>A (p.Val274Asp) SNV Likely Pathogenic
376675 rs1057520006 GRCh37: 17:7577117-7577117
GRCh38: 17:7673799-7673799
10 TP53 NM_000546.6(TP53):c.839G>T (p.Arg280Ile) SNV Likely Pathogenic
161517 rs121912660 GRCh37: 17:7577099-7577099
GRCh38: 17:7673781-7673781
11 TP53 NM_000546.6(TP53):c.577C>A (p.His193Asn) SNV Likely Pathogenic
376614 rs876658468 GRCh37: 17:7578272-7578272
GRCh38: 17:7674954-7674954
12 TP53 NM_000546.6(TP53):c.658T>G (p.Tyr220Asp) SNV Likely Pathogenic
376689 rs530941076 GRCh37: 17:7578191-7578191
GRCh38: 17:7674873-7674873
13 TP53 NM_000546.6(TP53):c.373A>C (p.Thr125Pro) SNV Likely Pathogenic
376666 rs1057520003 GRCh37: 17:7579314-7579314
GRCh38: 17:7675996-7675996
14 TP53 NM_000546.6(TP53):c.577C>G (p.His193Asp) SNV Likely Pathogenic
376613 rs876658468 GRCh37: 17:7578272-7578272
GRCh38: 17:7674954-7674954
15 TP53 NM_000546.6(TP53):c.659A>C (p.Tyr220Ser) SNV Likely Pathogenic
12383 rs121912666 GRCh37: 17:7578190-7578190
GRCh38: 17:7674872-7674872
16 TP53 NM_000546.6(TP53):c.374C>A (p.Thr125Lys) SNV Likely Pathogenic
216465 rs786201057 GRCh37: 17:7579313-7579313
GRCh38: 17:7675995-7675995
17 TP53 NM_000546.6(TP53):c.645T>G (p.Ser215Arg) SNV Likely Pathogenic
376661 rs1057520001 GRCh37: 17:7578204-7578204
GRCh38: 17:7674886-7674886
18 TP53 NM_000546.6(TP53):c.856G>C (p.Glu286Gln) SNV Likely Pathogenic
376591 rs786201059 GRCh37: 17:7577082-7577082
GRCh38: 17:7673764-7673764
19 TP53 NM_000546.6(TP53):c.731G>T (p.Gly244Val) SNV Likely Pathogenic
376601 rs985033810 GRCh37: 17:7577550-7577550
GRCh38: 17:7674232-7674232
20 TP53 NM_000546.6(TP53):c.820G>C (p.Val274Leu) SNV Likely Pathogenic
376678 rs1057520005 GRCh37: 17:7577118-7577118
GRCh38: 17:7673800-7673800
21 TP53 NM_000546.6(TP53):c.518T>C (p.Val173Ala) SNV Likely Pathogenic
376017 rs1057519747 GRCh37: 17:7578412-7578412
GRCh38: 17:7675094-7675094
22 TP53 NM_000546.6(TP53):c.644G>A (p.Ser215Asn) SNV Likely Pathogenic
376662 rs587782177 GRCh37: 17:7578205-7578205
GRCh38: 17:7674887-7674887
23 PTEN NM_000314.8(PTEN):c.388C>G (p.Arg130Gly) SNV Likely Pathogenic
375958 rs121909224 GRCh37: 10:89692904-89692904
GRCh38: 10:87933147-87933147
24 TP53 NM_000546.6(TP53):c.857A>T (p.Glu286Val) SNV Likely Pathogenic
376592 rs1057519985 GRCh37: 17:7577081-7577081
GRCh38: 17:7673763-7673763
25 TP53 NM_000546.6(TP53):c.730G>C (p.Gly244Arg) SNV Likely Pathogenic
376602 rs1057519989 GRCh37: 17:7577551-7577551
GRCh38: 17:7674233-7674233
26 TP53 NM_000546.6(TP53):c.857A>C (p.Glu286Ala) SNV Likely Pathogenic
376593 rs1057519985 GRCh37: 17:7577081-7577081
GRCh38: 17:7673763-7673763
27 PIK3CA NM_006218.4(PIK3CA):c.1624G>C (p.Glu542Gln) SNV Likely Pathogenic
376244 rs121913273 GRCh37: 3:178936082-178936082
GRCh38: 3:179218294-179218294
28 PIK3CA NM_006218.4(PIK3CA):c.1634A>C (p.Glu545Ala) SNV Likely Pathogenic
13659 rs121913274 GRCh37: 3:178936092-178936092
GRCh38: 3:179218304-179218304
29 PIK3CA NM_006218.4(PIK3CA):c.1625A>C (p.Glu542Ala) SNV Likely Pathogenic
376473 rs1057519927 GRCh37: 3:178936083-178936083
GRCh38: 3:179218295-179218295
30 AKT1 NM_001382430.1(AKT1):c.49G>A (p.Glu17Lys) SNV Likely Pathogenic
13983 rs121434592 GRCh37: 14:105246551-105246551
GRCh38: 14:104780214-104780214
31 PIK3CA NM_006218.4(PIK3CA):c.1625A>T (p.Glu542Val) SNV Likely Pathogenic
376474 rs1057519927 GRCh37: 3:178936083-178936083
GRCh38: 3:179218295-179218295
32 B2M NM_004048.4(B2M):c.2T>C (p.Met1Thr) SNV Likely Pathogenic
376371 rs1057519879 GRCh37: 15:45003746-45003746
GRCh38: 15:44711548-44711548
33 B2M NM_004048.4(B2M):c.2T>G (p.Met1Arg) SNV Likely Pathogenic
376372 rs1057519879 GRCh37: 15:45003746-45003746
GRCh38: 15:44711548-44711548
34 B2M NM_004048.4(B2M):c.1A>T (p.Met1Leu) SNV Likely Pathogenic
376370 rs1023835002 GRCh37: 15:45003745-45003745
GRCh38: 15:44711547-44711547
35 PIK3CA NM_006218.4(PIK3CA):c.1625A>G (p.Glu542Gly) SNV Likely Pathogenic
376475 rs1057519927 GRCh37: 3:178936083-178936083
GRCh38: 3:179218295-179218295
36 PIK3CA NM_006218.4(PIK3CA):c.1633G>C (p.Glu545Gln) SNV Likely Pathogenic
375896 rs104886003 GRCh37: 3:178936091-178936091
GRCh38: 3:179218303-179218303
37 PIK3CA NM_006218.4(PIK3CA):c.1634A>G (p.Glu545Gly) SNV Likely Pathogenic
13656 rs121913274 GRCh37: 3:178936092-178936092
GRCh38: 3:179218304-179218304
38 B2M NM_004048.4(B2M):c.3G>A (p.Met1Ile) SNV Likely Pathogenic
376368 rs1057519877 GRCh37: 15:45003747-45003747
GRCh38: 15:44711549-44711549
39 B2M NM_004048.4(B2M):c.1A>G (p.Met1Val) SNV Likely Pathogenic
376369 rs1023835002 GRCh37: 15:45003745-45003745
GRCh38: 15:44711547-44711547
40 PIK3CA NM_006218.4(PIK3CA):c.1635G>T (p.Glu545Asp) SNV Likely Pathogenic
217293 rs121913275 GRCh37: 3:178936093-178936093
GRCh38: 3:179218305-179218305
41 PIK3CA NM_006218.4(PIK3CA):c.1633G>A (p.Glu545Lys) SNV Likely Pathogenic
13655 rs104886003 GRCh37: 3:178936091-178936091
GRCh38: 3:179218303-179218303
42 TP53 NM_000546.6(TP53):c.487T>G (p.Tyr163Asp) SNV Likely Pathogenic
187052 rs786203436 GRCh37: 17:7578443-7578443
GRCh38: 17:7675125-7675125
43 TP53 NM_000546.6(TP53):c.839G>C (p.Arg280Thr) SNV Likely Pathogenic
12368 rs121912660 GRCh37: 17:7577099-7577099
GRCh38: 17:7673781-7673781
44 TP53 NM_000546.6(TP53):c.643A>G (p.Ser215Gly) SNV Likely Pathogenic
265337 rs886039484 GRCh37: 17:7578206-7578206
GRCh38: 17:7674888-7674888
45 TP53 NM_000546.6(TP53):c.838A>G (p.Arg280Gly) SNV Likely Pathogenic
376658 rs753660142 GRCh37: 17:7577100-7577100
GRCh38: 17:7673782-7673782
46 TP53 NM_000546.6(TP53):c.700T>C (p.Tyr234His) SNV Likely Pathogenic
376691 rs864622237 GRCh37: 17:7577581-7577581
GRCh38: 17:7674263-7674263
47 TP53 NM_000546.6(TP53):c.587G>C (p.Arg196Pro) SNV Likely Pathogenic
231165 rs483352697 GRCh37: 17:7578262-7578262
GRCh38: 17:7674944-7674944
48 TP53 NM_000546.6(TP53):c.535C>G (p.His179Asp) SNV Likely Pathogenic
376610 rs587780070 GRCh37: 17:7578395-7578395
GRCh38: 17:7675077-7675077
49 TP53 NM_000546.6(TP53):c.742C>T (p.Arg248Trp) SNV Likely Pathogenic
12347 rs121912651 GRCh37: 17:7577539-7577539
GRCh38: 17:7674221-7674221
50 TP53 NM_000546.6(TP53):c.644G>T (p.Ser215Ile) SNV Likely Pathogenic
376660 rs587782177 GRCh37: 17:7578205-7578205
GRCh38: 17:7674887-7674887

Cosmic variations for Lung Oat Cell Carcinoma:

8 (show top 50) (show all 1540)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM102042323 ZFHX3 lung,NS,carcinoma,undifferentiated carcinoma c.-23-8009A>G p.? 16:72958974-72958974 5
2 COSM87291734 ZFHX3 lung,NS,carcinoma,undifferentiated carcinoma c.1172A>G p.Q391R 16:72958974-72958974 5
3 COSM102040476 ZFHX3 lung,NS,carcinoma,undifferentiated carcinoma c.-23-8037G>T p.? 16:72959002-72959002 5
4 COSM149314749 ZFHX3 lung,NS,carcinoma,undifferentiated carcinoma c.1144G>T p.G382C 16:72959002-72959002 5
5 COSM87290218 ZFHX3 lung,NS,carcinoma,undifferentiated carcinoma c.1144G>T p.G382C 16:72959002-72959002 5
6 COSM149318860 ZFHX3 lung,NS,carcinoma,undifferentiated carcinoma c.1172A>G p.Q391R 16:72958974-72958974 5
7 COSM126973051 YAP1 lung,NS,carcinoma,undifferentiated carcinoma c.770C>T p.P257L 11:102229729-102229729 5
8 COSM145028029 YAP1 lung,NS,carcinoma,undifferentiated carcinoma c.1154C>T p.P385L 11:102229729-102229729 5
9 COSM128452039 YAP1 lung,NS,carcinoma,undifferentiated carcinoma c.1142C>T p.P381L 11:102229729-102229729 5
10 COSM85237448 YAP1 lung,NS,carcinoma,undifferentiated carcinoma c.1304C>T p.P435L 11:102229729-102229729 5
11 COSM143041512 YAP1 lung,NS,carcinoma,undifferentiated carcinoma c.1316C>T p.P439L 11:102229729-102229729 5
12 COSM127997731 YAP1 lung,NS,carcinoma,undifferentiated carcinoma c.1256C>T p.P419L 11:102229729-102229729 5
13 COSM133274224 YAP1 lung,NS,carcinoma,undifferentiated carcinoma c.1268C>T p.P423L 11:102229729-102229729 5
14 COSM90948266 YAP1 lung,NS,carcinoma,undifferentiated carcinoma c.1202C>T p.P401L 11:102229729-102229729 5
15 COSM108017622 XRCC6 lung,NS,carcinoma,undifferentiated carcinoma c.1009A>C p.I337L 22:41653558-41653558 5
16 COSM95166535 XRCC6 lung,NS,carcinoma,undifferentiated carcinoma c.1159A>C p.I387L 22:41653558-41653558 5
17 COSM97230831 XRCC6 lung,NS,carcinoma,undifferentiated carcinoma c.1159A>C p.I387L 22:41653558-41653558 5
18 COSM105839764 XRCC6 lung,NS,carcinoma,undifferentiated carcinoma c.1009A>C p.I337L 22:41653558-41653558 5
19 COSM106337415 XRCC6 lung,NS,carcinoma,undifferentiated carcinoma c.1159A>C p.I387L 22:41653558-41653558 5
20 COSM103711109 XRCC6 lung,NS,carcinoma,undifferentiated carcinoma c.1036A>C p.I346L 22:41653558-41653558 5
21 COSM85312404 XRCC1 lung,NS,carcinoma,undifferentiated carcinoma c.1207A>G p.M403V 19:43546970-43546970 5
22 COSM134125623 XRCC1 lung,NS,carcinoma,undifferentiated carcinoma c.1114A>G p.M372V 19:43546970-43546970 5
23 COSM100781761 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.724A>T p.K242* 11:32392044-32392044 5
24 COSM111539040 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.1309A>T p.K437* 11:32392044-32392044 5
25 COSM149728755 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.437G>A p.W146* 11:32434909-32434909 5
26 COSM130518653 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.673A>T p.K225* 11:32392044-32392044 5
27 COSM113475703 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.437G>A p.W146* 11:32434909-32434909 5
28 COSM111529696 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.437G>A p.W146* 11:32434909-32434909 5
29 COSM113484991 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.1360A>T p.K454* 11:32392044-32392044 5
30 COSM147414475 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.437G>A p.W146* 11:32434909-32434909 5
31 COSM149739953 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.1360A>T p.K454* 11:32392044-32392044 5
32 COSM148580942 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.437G>A p.W146* 11:32434909-32434909 5
33 COSM148593279 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.1360A>T p.K454* 11:32392044-32392044 5
34 COSM91372655 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.437G>A p.W146* 11:32434909-32434909 5
35 COSM91383011 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.1360A>T p.K454* 11:32392044-32392044 5
36 COSM147426277 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.1309A>T p.K437* 11:32392044-32392044 5
37 COSM124478343 WNT8A lung,NS,carcinoma,undifferentiated carcinoma c.422G>C p.G141A 5:138088927-138088927 5
38 COSM104050903 WNT8A lung,NS,carcinoma,undifferentiated carcinoma c.368G>C p.G123A 5:138088927-138088927 5
39 COSM105123686 WNT10B lung,NS,carcinoma,undifferentiated carcinoma c.*288A>C p.? 12:48966259-48966259 5
40 COSM87652733 WNT10B lung,NS,carcinoma,undifferentiated carcinoma c.1006A>C p.K336Q 12:48966259-48966259 5
41 COSM102763785 WNT10B lung,NS,carcinoma,undifferentiated carcinoma c.*288A>C p.? 12:48966259-48966259 5
42 COSM99767946 USP5 lung,NS,carcinoma,undifferentiated carcinoma c.755C>T p.T252I 12:6856877-6856877 5
43 COSM84601598 USP5 lung,NS,carcinoma,undifferentiated carcinoma c.755C>T p.T252I 12:6856877-6856877 5
44 COSM121848752 USP38 lung,NS,carcinoma,undifferentiated carcinoma c.994G>C p.A332P 4:143197868-143197868 5
45 COSM88410243 USP38 lung,NS,carcinoma,undifferentiated carcinoma c.994G>C p.A332P 4:143197868-143197868 5
46 COSM87541563 USP32 lung,NS,carcinoma,undifferentiated carcinoma c.192T>A p.I64= 17:60301699-60301699 5
47 COSM99795256 USP32 lung,NS,carcinoma,undifferentiated carcinoma c.192T>A p.I64= 17:60301699-60301699 5
48 COSM143996084 UHRF1 lung,NS,carcinoma,undifferentiated carcinoma c.1620C>G p.F540L 19:4947122-4947122 5
49 COSM143964403 UHRF1 lung,NS,carcinoma,undifferentiated carcinoma c.1428C>G p.F476L 19:4947122-4947122 5
50 COSM145430147 UHRF1 lung,NS,carcinoma,undifferentiated carcinoma c.1467C>G p.F489L 19:4947122-4947122 5

Expression for Lung Oat Cell Carcinoma

Search GEO for disease gene expression data for Lung Oat Cell Carcinoma.

Pathways for Lung Oat Cell Carcinoma

Pathways related to Lung Oat Cell Carcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 64)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.59 TP53 RB1 PTEN POMC PIK3CA B2M
2
Show member pathways
13.21 TP53 POMC PIK3CA B2M AKT1
3 12.6 TP53 PTEN PIK3CA AKT1
4
Show member pathways
12.54 TP53 RB1 PIK3CA AKT1
5
Show member pathways
12.53 AKT1 PIK3CA PTEN RB1 TP53
6 12.48 SYP POMC ENO2 AVP
7
Show member pathways
12.34 TP53 PTEN PIK3CA AKT1
8 12.2 PTEN PIK3CA AKT1
9
Show member pathways
12.2 AKT1 PIK3CA PTEN RB1 TP53
10
Show member pathways
12.19 PTEN PIK3CA AKT1
11
Show member pathways
12.11 TP53 PTEN PIK3CA AKT1
12 12.09 TP53 PIK3CA AKT1
13
Show member pathways
12.06 TP53 RB1 PTEN AKT1
14
Show member pathways
12.04 PTEN PIK3CA AKT1
15
Show member pathways
12.03 TP53 PIK3CA AKT1
16
Show member pathways
12.02 TP53 RB1 AKT1
17 12.01 AKT1 PTEN TP53
18 11.99 SYP PTEN AKT1
19
Show member pathways
11.99 TP53 RB1 PTEN PIK3CA AKT1
20
Show member pathways
11.98 TP53 PTEN PIK3CA AKT1
21 11.97 TP53 RB1 PTEN
22 11.96 TP53 RB1 PTEN AKT1
23
Show member pathways
11.94 TP53 PIK3CA AKT1
24
Show member pathways
11.92 PTEN PIK3CA AKT1
25
Show member pathways
11.89 AKT1 PIK3CA PTEN
26 11.89 AKT1 CHGA PIK3CA
27 11.87 TP53 POMC AKT1
28 11.86 TP53 RB1 PTEN
29 11.84 TP53 PTEN PIK3CA
30 11.78 PTEN PIK3CA AKT1
31 11.75 TP53 PTEN AKT1
32 11.73 AKT1 ENO2 PTEN
33 11.72 TP53 POMC PIK3CA
34
Show member pathways
11.69 TP53 PIK3CA AKT1
35 11.67 TP53 POMC AKT1
36
Show member pathways
11.59 TP53 PIK3CA AKT1
37 11.58 PTEN PIK3CA AKT1
38
Show member pathways
11.55 RB1 PIK3CA AKT1
39 11.54 TP53 RB1 POMC
40 11.52 AKT1 PIK3CA RB1
41 11.46 TP53 PIK3CA AKT1
42 11.42 TP53 PTEN PIK3CA AKT1
43 11.39 PTEN PIK3CA AKT1
44 11.34 TP53 RB1 PTEN PIK3CA AKT1
45
Show member pathways
11.32 TP53 PTEN PIK3CA AKT1
46 11.13 PIK3CA AKT1
47 11.11 PIK3CA AKT1
48 11.11 PTEN PIK3CA AKT1
49 11.1 PIK3CA AKT1
50 11.08 AKT1 PIK3CA

GO Terms for Lung Oat Cell Carcinoma

Biological processes related to Lung Oat Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of gene expression GO:0010629 10.04 TP53 RB1 PIK3CA AKT1
2 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.91 PIK3CA AVP AKT1
3 negative regulation of epithelial cell proliferation GO:0050680 9.85 B2M PTEN RB1
4 maternal behavior GO:0042711 9.78 PTEN AVP
5 anoikis GO:0043276 9.76 PIK3CA AKT1
6 negative regulation of neuron death GO:1901215 9.73 ENO2 CHGA AKT1
7 cell population proliferation GO:0008283 9.72 TP53 RB1 PTEN AKT1
8 negative regulation of glial cell proliferation GO:0060253 9.71 TP53 RB1
9 protein kinase B signaling GO:0043491 9.63 PTEN PIK3CA AKT1
10 phosphatidylinositol 3-kinase signaling GO:0014065 9.43 PTEN PIK3CA AKT1
11 cellular response to decreased oxygen levels GO:0036294 8.8 PTEN AKT1

Molecular functions related to Lung Oat Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.8 TP53 SYP RB1 PTEN ENO2 B2M
2 enzyme binding GO:0019899 9.28 TP53 RB1 PTEN ENO2 AKT1

Sources for Lung Oat Cell Carcinoma

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....